Ed Esplin

Dr. Ed Esplin, MD, PhD, FACMG, CGAF, FACP, is a clinical geneticist and physician-scientist with extensive experience in cancer, cardiomyopathy, and genetic disease research. They served as Medical Officer and Clinical Geneticist at Invitae from 2014 to 2025, playing a vital role in the company's FDA de novo market authorization for a hereditary cancer panel. Currently, Dr. Esplin leads research and clinical trials at Labcorp Genetics and holds an academic appointment at Stanford University, where they also co-author scientific papers in the field. They completed their MD and PhD at UT Southwestern and have held various academic and advisory roles throughout their career.